NCT00167219View on ClinicalTrials.gov

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 18, 1999

Primary Completion Date

July 12, 2022

Study Completion Date

August 9, 2023

Conditions
Juvenile Myelomonocytic Leukemia
Interventions
BIOLOGICAL

Stem Cell Transplant

Transplantation on Day 0.

DRUG

Preparative Regimen

"* Busulfan~* Cyclophosphamide~* Mesna~* Melphalan~* Anti-thymocyte Globulin (ATG)"

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00167219 - Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | Biotech Hunter | Biotech Hunter